Modeling, simulation firm supporting radiation countermeasure development

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BreakingTheWalls)
(Image: Getty/BreakingTheWalls)

Related tags Modeling and simulation

The modeling and simulation solutions provider Simulations Plus has been contracted to support countermeasure development for acute radiation syndrome in a partnership with a global pharma company.

An SLP company, DILIsym Services (DSS), is leading the development of RADAsym, a new quantitative systems pharmacology (QPS) platform.

Cognigen also will be working directly with the sponsor to curate data and support pharmacometric modeling activities.

The technology helps predict the effects of radiation in mice, non-human primates, and humans, in addition to the efficacy of interventions.

It will be used to help support approval for acute radiation syndrome (ARS) treatment under the Animal Rule, regulations which enable the approval of drugs and licensure of biological products in situations where human efficacy studies are not ethical or feasible.

The QPS platform will include major biological systems, including the vasculature and immune systems, the liver and GI tract, as well as the lung and bone marrow.

In the future, the RADAsym platform will be available for licensing and consulting services.

Said Shawn O’Connor, Simulations Plus CEO: "We are pleased to have been engaged by industry to support this critical development effort. Our expertise across QSP and PKPD techniques and model development positions us uniquely to satisfy the requirements of this endeavor. This engagement also demonstrates our ability to cross-sell the capabilities of our divisions.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more